A
1.22
0.01 (0.41%)
| 前收盘价格 | 1.21 |
| 收盘价格 | 1.21 |
| 成交量 | 7,299,575 |
| 平均成交量 (3个月) | 5,860,164 |
| 市值 | 419,771,424 |
| 价格/销量 (P/S) | 91.86 |
| 股市价格/股市净资产 (P/B) | 1.33 |
| 52周波幅 | |
| 利润日期 | 5 Nov 2026 |
| 稀释每股收益 (EPS TTM) | -1.22 |
| 季度收入增长率 (YOY) | -100.00% |
| 总债务/股东权益 (D/E MRQ) | 23.07% |
| 流动比率 (MRQ) | 9.71 |
| 营业现金流 (OCF TTM) | -197.33 M |
| 杠杆自由现金流 (LFCF TTM) | -96.65 M |
| 资产报酬率 (ROA TTM) | -28.92% |
| 股东权益报酬率 (ROE TTM) | -59.60% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | Allogene Therapeutics, Inc. | 混合的 | 看跌 |
AIStockmoo 评分
0.1
| 分析师共识 | NA |
| 内部交易活动 | NA |
| 价格波动 | 0.5 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | -2.5 |
| 相对估值 | NA |
| 财务健康 | NA |
| 宏观环境 | 0.0 |
| AI Insight | NA |
| 平均 | 0.13 |
|
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC). |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 17.70% |
| 机构持股比例 | 81.75% |
该时间范围内无数据。
该时间范围内无数据。
投资组合